Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BTAI 
BioXcel Therapeutics Inc (BTAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: BTAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.25
1 Year Target Price $23.25
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.41% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.96M USD | Price to earnings Ratio - | 1Y Target Price 23.25 |
Price to earnings Ratio - | 1Y Target Price 23.25 | ||
Volume (30-day avg) 3 | Beta -0.13 | 52 Weeks Range 1.17 - 21.92 | Updated Date 06/30/2025 |
52 Weeks Range 1.17 - 21.92 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6011.31% |
Management Effectiveness
Return on Assets (TTM) -52.47% | Return on Equity (TTM) -1766.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 85824443 | Price to Sales(TTM) 5.92 |
Enterprise Value 85824443 | Price to Sales(TTM) 5.92 | ||
Enterprise Value to Revenue 46.34 | Enterprise Value to EBITDA -0.75 | Shares Outstanding 6056050 | Shares Floating 5544250 |
Shares Outstanding 6056050 | Shares Floating 5544250 | ||
Percent Insiders 8.65 | Percent Institutions 11.02 |
Analyst Ratings
Rating 2 | Target Price 23.25 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioXcel Therapeutics Inc
Company Overview
History and Background
BioXcel Therapeutics Inc. was founded in 2010. It is a biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.
Core Business Areas
- Neuroscience: Development and commercialization of treatments for acute agitation and other neurological and psychiatric disorders. Lead product is BXCL501 (dexmedetomidine) film, branded as Igalmi, for acute agitation.
- Immuno-oncology: Utilizing AI to identify novel targets and develop therapies for cancer indications. This area is in early stage development and preclinical trials.
Leadership and Structure
The company is led by Vimal Mehta, PhD, as CEO. The organizational structure includes research and development, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Igalmi (BXCL501): A sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Igalmi has secured roughly 20% of the market for acute agitation treatment in its first year. Key competitors include traditional antipsychotics and benzodiazepines. Revenue data is not readily available, but is steadily growing.
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and rapidly evolving, with a focus on developing innovative therapies for unmet medical needs. The market is driven by aging populations, increasing prevalence of chronic diseases, and technological advancements.
Positioning
BioXcel Therapeutics is positioned as an innovative biopharmaceutical company leveraging AI for drug discovery and development. Their competitive advantage lies in their AI platform and the novel mechanism of action of Igalmi.
Total Addressable Market (TAM)
The TAM for acute agitation treatment is estimated to be significant, with millions of individuals experiencing agitation episodes annually. BioXcel is gaining market share with Igalmi, suggesting strong potential.
Upturn SWOT Analysis
Strengths
- Novel AI platform for drug discovery
- FDA-approved product (Igalmi)
- Focus on unmet medical needs in neuroscience and immuno-oncology
- Experienced management team
Weaknesses
- Reliance on a single approved product
- Limited commercialization experience
- High cash burn rate
- Dependence on successful development of pipeline candidates
Opportunities
- Expansion of Igalmi's indications
- Development of new therapies through AI platform
- Strategic partnerships and collaborations
- Increasing awareness of acute agitation as a treatable condition
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Reimbursement challenges
- Generic competition for Igalmi after patent expiration
Competitors and Market Share
Key Competitors
- TEVA
- MYL
Competitive Landscape
BioXcel faces competition from established pharmaceutical companies with broader product portfolios and greater resources. BioXcel's advantage lies in its AI platform and the novel mechanism of action of Igalmi.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by significant R&D investment, clinical trial progress, and initial commercialization of Igalmi.
Future Projections: Future growth is dependent on the continued adoption of Igalmi, successful development of pipeline candidates, and strategic partnerships. Analyst projections suggest revenue growth but continued losses in the near term.
Recent Initiatives: Recent initiatives include expanding the sales force for Igalmi, advancing clinical trials for BXCL701 (immuno-oncology program), and exploring potential partnerships.
Summary
BioXcel Therapeutics is an innovative company focused on neuroscience and immuno-oncology, but it is also a high-risk investment. Igalmi's successful commercialization and growing adoption are positive signs. The company needs to manage its cash flow carefully and continue to advance its pipeline to support long-term growth, particularly within the financial constraints it is currently operating under. The AI platform holds promise, but its impact on future products remains to be seen.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioXcel Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-03-08 | Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | |
Full time employees 37 | |||
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.